News-Medical.Net on MSN
Verapamil shows potential for preserving beta-cell function in type 1 diabetes
New research (the Ver-A-T1D trial) presented at this year's Annual Meeting of the European Association for the Study of ...
New data suggest antithymocyte globulin, verapamil, and baricitinib might help preserve beta cell function in new-onset type ...
In preclinical models, rat insulinoma‑derived beta‑cell line INS‑1 (INS‑1) cells and mouse islets showed rapid, robust ...
2don MSN
Fresh hope for type 1 diabetes as daily pill that slows onset confirms promise at two-year follow-up
In 2023, the groundbreaking Australian BANDIT (Baricitinib in New Onset Type 1 Diabetes) trial reported that a daily pill of ...
Biomea Fusion, Inc. announced positive results from preclinical experiments showing that its investigational drug icovamenib enhances beta cell function and improves the responsiveness of human islets ...
In a rodent model of T2D, icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with ...
Therapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in beta-cell function 3 months after last dose, suggesting disease-modifying potential of ...
P olyclonal antithymocyte globulin (ATG), an old agent used to suppress the immune system and destroy T cells, reduced the ...
ZyVersa Therapeutics (ZVSA) highlights data from an article published in the peer-reviewed International Journal of Nanomedicine titled Small Intestinal Endocrine Cell Derived Exosomal ACE2 Protects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback